SEC Comment Letter 0000000000-23-008984 to PaxMedica, Inc. (PXMD) (CIK 0001811623)
PaxMedica, Inc. (PXMD) (CIK 0001811623)
Date: Aug. 17, 2023 · CIK: 0001811623 · Accession: 0000000000-23-008984
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo August 17, 2023 Stephen Sheldon Chief Financial Officer PaxMedica, Inc. 303 South Broadway, Suite 315 Tarrytown, NY 10036 Re:PaxMedica, Inc. Draft Registration Statement on Form S-1 Submitted August 10, 2023 CIK No. 0001811623 Dear Stephen Sheldon: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna Tomczyk, Esq.
Show Raw Text
United States securities and exchange commission logo
August 17, 2023
Stephen Sheldon
Chief Financial Officer
PaxMedica, Inc.
303 South Broadway, Suite 315
Tarrytown, NY 10036
Re:PaxMedica, Inc.
Draft Registration Statement on Form S-1
Submitted August 10, 2023
CIK No. 0001811623
Dear Stephen Sheldon:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anna Tomczyk, Esq.